NEW YORK, Oct. 31, 2024 /PRNewswire/ -- Report with market evolution powered by AI - The global hypothyroidism market size is estimated to grow by USD 789.8 million from 2024-2028, according to Technavio.
The market is estimated to grow at a CAGR of 6.8% during the forecast period. Increasing approval of new hypothyroidism drugs is driving market growth, with a trend towards inorganic growth strategies among market vendors.
However, product recall in global hypothyroidism market poses a challenge market players include AbbVie Inc., AdvaCare Pharma, Alvogen Inc, Aurore Life Sciences Pvt Ltd, Biophore India Pharmaceuticals Pvt. Ltd.
, IBSA Institut Biochimique SA, JEROME STEVENS PHARMACEUTICALS INC., LLOYD Inc., Lupin Ltd.
, Merck KGaA, Novartis AG, Pfizer Inc., RLC Labs Inc., Sigmapharm Laboratories LLC, Sun Pharmaceutical Industries Ltd.
, Teva Pharmaceutical Industries Ltd., Viatris Inc., Wockhardt Ltd.
, and Zydus Lifesciences Ltd.. AI-Powered Market Evolution Insights.
Our comprehensive market report ready with the latest trends, growth opportunities, and strategic analysis- View your snapshot now Forecast period 2024-2028 Base Year 2023 Historic Data 2018 - 2022 Segment Covered Disease Type (Primary hypothyroidism, Secondary hypothyroidism, and Others), Distribution Channel (Hospital pharmacy, Retail pharmacy, and Online pharmacy), and Geography (North America, Europe, Asia, and Rest of World (ROW)) Region Covered North America, Europe, Asia, and Rest of World (ROW) Key compa.
